Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting
May 09 2022 - 12:11PM
Nuwellis, Inc. (Nasdaq: NUWE) today announced the presentation of
three Aquadex-related abstracts at the annual Pediatric Academic
Societies (PAS) meeting. This research was funded in part by
unrestricted grants by Nuwellis to the University of Alabama at
Birmingham (UAB). Other sources of funding included the
Nuwellis-funded Ultrafiltration Therapy Registry using Aquadex –
Pediatric (ULTRA-Peds) and the National Kidney Collaborative (NKC).
PAS, the premier national meeting for pediatric research, was held
in Denver, Colorado from April 21-25, 2022.
“We are excited to add to the ever-growing body of research
supporting the negative impact of fluid excess and the benefits of
Aquadex,” said Nestor Jaramillo, Jr., President and CEO of
Nuwellis. “I’m grateful to the leader of these projects, Dr. David
Askenazi, for his thoughtful research on the benefits of
ultrafiltration for pediatric patients.”
Aquadex SmartFlow® ultrafiltration enables gentle, precise, and
adjustable fluid removal, helping achieve the desired fluid balance
with only 35 mL (around 2.5 tablespoons) of blood outside of the
body. The customizable rate of fluid removal is particularly
important for pediatric patients, who have a small amount of blood
in their bodies. Aquadex is cleared by the FDA for use in adults
and pediatric patients weighing 20 kg (44 lbs.) or more.
“Ultrafiltration using the Aquadex system provides an easy to
use, safe and effective therapy for managing fluid balance in
pediatric patients,” said Dr. Askenazi. “I’m grateful for the
commitment from the company and I’m proud to partner with Nuwellis
to provide meaningful data that helps the medical community
determine when and how to implement Aquadex for those who suffer
from pediatric kidney disease.”
About NuwellisNuwellis, Inc. (Nasdaq: NUWE) is
a medical device company dedicated to transforming the lives of
patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
developing, manufacturing, and commercializing the Aquadex
SmartFlow® system for ultrafiltration therapy. Nuwellis is
headquartered in Minneapolis, Minn., with a wholly-owned subsidiary
in Ireland.
About the Aquadex SmartFlow SystemThe Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible, and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking StatementsCertain statements in
this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the new
market opportunities and anticipated growth in 2022 and beyond.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our ability to execute on our commercialization strategy, the
impact of the COVID-19 pandemic, the possibility that we may be
unable to raise sufficient funds necessary for our anticipated
operations, our post-market clinical data collection activities,
benefits of our products to patients, our expectations with respect
to product development and commercialization efforts, our ability
to increase market and physician acceptance of our products,
potentially competitive product offerings, intellectual property
protection, our ability to integrate acquired businesses, our
expectations regarding anticipated synergies with and benefits from
acquired businesses, and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak only as
of the date when made. Nuwellis does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
CONTACTS
INVESTORS:
George Montague, CFA
Chief Financial Officer, Nuwellis, Inc.
ir@nuwellis.com
Matt Bacso, CFA
Gilmartin Group LLC
Matt.Bacso@gilmartinir.com
MEDIA:
Sarah Lundberg
Health+Commerce
sarahlundberg@healthandcommerce.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jul 2023 to Jul 2024